Analysis says secret Trump pharma deals could cut projected Medicare savings from MFN pricing by up to 80%

A new analysis warns that confidential agreements between the Trump administration and more than two dozen drug makers could dramatically shrink the savings expected from the "most‑favored‑nation" pricing strategy.

The policy would link Medicare drug prices to the lowest prices paid by 19 wealthy nations, with the White House projecting $26 billion in savings over several years. Two pilot programs, GLOBE for Part B and GUARD for Part D, would require additional rebates if U.S. prices exceed those international benchmarks.

According to the analysis, the secret deals may reduce the anticipated savings by as much as 80%, calling into question the effectiveness of the MFN approach and its impact on drug affordability.